Litigation Details for Hartig Drug Company Inc. v. Senju Pharmaceutical Co. Ltd. (D. Del. 2014)
✉ Email this page to a colleague
Hartig Drug Company Inc. v. Senju Pharmaceutical Co. Ltd. (D. Del. 2014)
Docket | ⤷ Sign Up | Date Filed | 2014-06-06 |
Court | District Court, D. Delaware | Date Terminated | 2018-11-12 |
Cause | 15:1 Antitrust Litigation | Assigned To | Joseph F. Bataillon |
Jury Demand | Plaintiff | Referred To | Sherry R. Fallon |
Patents | 6,333,045 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Hartig Drug Company Inc. v. Senju Pharmaceutical Co. Ltd.
Details for Hartig Drug Company Inc. v. Senju Pharmaceutical Co. Ltd. (D. Del. 2014)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2014-06-06 | 1 | 2001, the patent application naming lnada and Yasueda issued as U.S. Patent No. 6,333,045 (“the ‘045…scope of the patent) that new drug in the United States for the duration of the patents, Patent holders may…filed patent information with the FDA (a “Paragraph l certification”); b. The patent or patents listed…Kyorin in 1990 in U.S. Patent No. 4,980,470 (“the ‘470 patent”). The ‘470 patent, which expired on June…listed three patents in the Orange Book for NDA No. 21-493: the ‘470 patent, the ‘045 patent, and U.S. | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |